DE3751470T2 - Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen. - Google Patents

Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.

Info

Publication number
DE3751470T2
DE3751470T2 DE3751470T DE3751470T DE3751470T2 DE 3751470 T2 DE3751470 T2 DE 3751470T2 DE 3751470 T DE3751470 T DE 3751470T DE 3751470 T DE3751470 T DE 3751470T DE 3751470 T2 DE3751470 T2 DE 3751470T2
Authority
DE
Germany
Prior art keywords
pentigetide
ige
treatment
inflammatory diseases
mediated inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3751470T
Other languages
English (en)
Other versions
DE3751470D1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dura Pharmaceuticals Inc
Original Assignee
Dura Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dura Pharmaceuticals Inc filed Critical Dura Pharmaceuticals Inc
Publication of DE3751470D1 publication Critical patent/DE3751470D1/de
Application granted granted Critical
Publication of DE3751470T2 publication Critical patent/DE3751470T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DE3751470T 1986-12-09 1987-12-09 Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen. Expired - Fee Related DE3751470T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/939,927 US4816449A (en) 1984-08-09 1986-12-09 Immunotherapeutic anti-inflammatory peptide agents
PCT/US1987/003222 WO1988004177A1 (en) 1986-12-09 1987-12-09 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-IgE-MEDIATED DISEASES

Publications (2)

Publication Number Publication Date
DE3751470D1 DE3751470D1 (de) 1995-09-21
DE3751470T2 true DE3751470T2 (de) 1996-04-04

Family

ID=25473943

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3751470T Expired - Fee Related DE3751470T2 (de) 1986-12-09 1987-12-09 Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.

Country Status (8)

Country Link
US (1) US4816449A (de)
EP (1) EP0335901B1 (de)
JP (2) JPH02501573A (de)
AT (1) ATE126441T1 (de)
AU (2) AU612341B2 (de)
DE (1) DE3751470T2 (de)
DK (2) DK442688A (de)
WO (2) WO1988004177A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468730A (en) * 1984-08-09 1995-11-21 Dura Pharmaceuticals, Inc. Methods for the treatment of non-IgE-mediated diseases
US5061692A (en) * 1984-08-09 1991-10-29 Immunetech Pharmaceuticals Methods and compositions for the treatment of non-IgE-mediated diseases
GB8905606D0 (en) * 1989-03-11 1989-04-26 Scras Peptides
DK122489D0 (da) * 1989-03-14 1989-03-14 Carlsberg Biotechnology Ltd Fremgangsmaade til fremstilling af pentapeptider samt mellemprodukter til brug ved fremstillingen
US5252464A (en) * 1989-03-14 1993-10-12 Carlsberg Biotechnology Ltd. A/S Process for producing pentapeptides and intermediates for use in the synthesis
US5268455A (en) * 1989-05-25 1993-12-07 Genentech, Inc. Process for making biologically active polypeptides based on transforming growth factor-βsequences
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
US5028593A (en) * 1989-08-15 1991-07-02 Board Of Regents, The University Of Texas System Tuftsin analogs
US5118669A (en) * 1989-09-20 1992-06-02 Hitachi Chemical Co., Ltd. Peptides and intermediates therefor useful as antiallergic agents, vasodilators and immunoregulators
US5223487A (en) * 1989-09-30 1993-06-29 Hitachi Chemical Co., Ltd. Peptides as antiallergic agents
US5776892A (en) * 1990-12-21 1998-07-07 Curative Health Services, Inc. Anti-inflammatory peptides
US5250293A (en) * 1991-04-22 1993-10-05 Gleich Gerald J Method for the treatment of hypersensitivity diseases by administration of anionic polymers
US5681555A (en) * 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
US5498410A (en) * 1991-04-22 1996-03-12 Gleich; Gerald J. Method for the treatment of eosinophil-associated conditions with anionic polymers
DK0510912T3 (da) * 1991-04-24 1998-02-09 Morinaga Milk Industry Co Ltd Antimikrobielt peptid og antimikrobielt middel
GB9211668D0 (en) * 1992-06-02 1992-07-15 Nycomed Bioreg As Peptide compounds
US6177405B1 (en) * 1992-07-22 2001-01-23 Kenji Nishioka Cyclic analogs of tuftsin
DE4237456A1 (de) * 1992-11-06 1994-05-11 Merck Patent Gmbh Cyclopeptide
US5705481A (en) * 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
IL108031A0 (en) * 1992-12-22 1994-04-12 Procter & Gamble Difluoro pentapeptide derivatives and pharmaceutical compositions containing them
ATE276272T1 (de) * 1993-06-18 2004-10-15 Curative Tech Inc Entzündungshemmende peptide
GB9320897D0 (en) * 1993-10-11 1993-12-01 Peptide Therapeutics Ltd Compounds useful in anti-allergy treatment
US7404967B2 (en) * 1994-12-21 2008-07-29 Cosmederm, Inc. Topical product formulations containing strontium for reducing skin irritation
US6139850A (en) * 1994-12-21 2000-10-31 Cosmederm Technologies Formulations and methods for reducing skin irritation
GB9509957D0 (en) * 1995-05-17 1995-07-12 Khalil Nasreen Post-translational activation of tgf-›1 involving the tsp-1 receptor cd36
US20030202980A1 (en) * 1995-12-29 2003-10-30 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
EP1049795A1 (de) 1998-01-20 2000-11-08 Myriad Genetics, Inc. Mmsc1, ein mit mmac1 interagierendes protein
JP2002501748A (ja) * 1998-01-31 2002-01-22 ユニバーシティ オブ アーカンソー アレルギー反応を減少させるための方法および試薬
US7879977B2 (en) 1998-01-31 2011-02-01 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6767890B1 (en) * 1998-11-18 2004-07-27 Coastside Bio Resources Peptides having anti-cancer and anti-inflammatory activity
US20030158111A1 (en) * 1999-10-01 2003-08-21 David Bar-Or Methods and products for oral care
US7592304B2 (en) * 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US20030130185A1 (en) * 2000-09-29 2003-07-10 David Bar-Or Metal-binding compounds and uses therefor
EP1272213B1 (de) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbielles wirkstoffabgabesystem
US8246945B2 (en) * 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20050063994A1 (en) * 2000-04-06 2005-03-24 Caplan Michael J. Methods and reagents for decreasing clinical reaction to allergy
US6908899B2 (en) * 2001-08-17 2005-06-21 U.S. Dept. Of Veterans Affairs Pro-inflammatory fibrinopeptide
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
JP4511173B2 (ja) * 2001-08-24 2010-07-28 マイジェニックス インコーポレイテッド 抗菌性および抗炎症性ペプチド
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
MXPA04001804A (es) * 2001-08-30 2005-03-07 Biorexis Pharmaceutical Corp Proteinas de fusion de transferrina modificada.
US20070031440A1 (en) * 2001-08-30 2007-02-08 Prior Christopher P Modified transferin-antibody fusion proteins
US20030226155A1 (en) * 2001-08-30 2003-12-04 Biorexis Pharmaceutical Corporation Modified transferrin-antibody fusion proteins
CN102268094A (zh) * 2002-08-30 2011-12-07 比奥雷克西斯药物公司 被修饰的转铁蛋白抗体的融合蛋白
US20060105387A1 (en) * 2002-08-30 2006-05-18 Prior Christopher P Transferrin fusion proteins libraries
ATE439853T1 (de) * 2002-11-20 2009-09-15 Arriva Prometic Inc Zusammensetzung zur behandlung von ichthyosis unter verwendung von antitrypsin
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
EP1620066A4 (de) * 2003-05-07 2010-11-03 Dmi Biosciences Inc Mundpflegeverfahren und -produkte
US20070275871A1 (en) * 2003-08-28 2007-11-29 Biorexis Technology, Inc. Epo Mimetic Peptides and Fusion Proteins
US20060205037A1 (en) * 2003-08-28 2006-09-14 Homayoun Sadeghi Modified transferrin fusion proteins
CN1886126A (zh) * 2003-09-25 2006-12-27 Dmi生物科学公司 利用n－酰基－l－天冬氨酸的方法和产品
EP1568707A1 (de) * 2004-02-26 2005-08-31 Puleva Biotech, S.A. Blutdrucksenkenden Peptiden aus Kaseinhydrolysaten
AU2007278994B2 (en) * 2006-07-24 2013-08-15 Biorexis Pharmaceutical Corporation Exendin fusion proteins
US8697840B2 (en) * 2008-03-05 2014-04-15 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
CN117679487A (zh) 2013-03-15 2024-03-12 得克萨斯州大学系统董事会 用Nutlin-3a和肽抑制肺纤维化
KR101632948B1 (ko) * 2014-05-13 2016-06-27 (주)케어젠 항염증, 골 형성 및 발모 촉진 활성을 갖는 펩타이드 및 이의 용도
US11905336B2 (en) 2018-09-10 2024-02-20 Lung Therapeutics, Inc. Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis
CN113677404B (zh) 2019-03-26 2024-03-29 卢卡斯梅耶化妆品公司 聚赖氨酸树枝状聚合物在预防和管理易出现痤疮的皮肤和痤疮皮肤中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065808A (en) * 1975-01-25 1977-12-27 U.S. Philips Corporation Network computer system
US4171299A (en) * 1975-04-04 1979-10-16 The Regents Of The University Of California Polypeptide agents for blocking the human allergic response
DE2602443A1 (de) * 1975-04-04 1976-10-21 Univ California Biologisch aktive polypeptide
US4392997A (en) * 1981-07-06 1983-07-12 Northwestern University Antigenic peptide compounds
US4814973A (en) * 1983-05-31 1989-03-21 Hillis W Daniel Parallel processor
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
US4579840A (en) * 1983-08-12 1986-04-01 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin Fc receptors
US4686282A (en) * 1983-08-12 1987-08-11 Immunetech, Inc. Immunotherapeutic polypeptide agents which block immune complex binding to immunoglobulin Fc receptors
JPH07120275B2 (ja) * 1983-12-28 1995-12-20 株式会社日立製作所 シミューションプログラム生成方法
US4692511A (en) * 1984-07-03 1987-09-08 Immunetech Pharmaceuticals Peptide antagonists for the C5a anaphylatoxin
ZA846192B (en) * 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents

Also Published As

Publication number Publication date
DK442688A (da) 1988-10-07
DK442688D0 (da) 1988-08-08
DE3751470D1 (de) 1995-09-21
DK442788D0 (da) 1988-08-08
EP0335901A4 (en) 1990-11-28
JPH02501066A (ja) 1990-04-12
EP0335901A1 (de) 1989-10-11
WO1988004178A1 (en) 1988-06-16
ATE126441T1 (de) 1995-09-15
AU1049788A (en) 1988-06-30
DK442788A (da) 1988-10-07
JPH02501573A (ja) 1990-05-31
AU612341B2 (en) 1991-07-11
AU1056788A (en) 1988-06-30
US4816449A (en) 1989-03-28
WO1988004177A1 (en) 1988-06-16
EP0335901B1 (de) 1995-08-16

Similar Documents

Publication Publication Date Title
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE131068T1 (de) Behandlung von pathologischen zuständen und krankheiten.
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE3884622D1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3685633T2 (de) Behandlung von knochenstoerungen.
DE3587741T2 (de) Behandlung von Hautkrankheiten.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
DE3750934T2 (de) Behandlung von nicht-Akne-entzündlichen und -infektiösen Hautkrankheiten.
DE68910175D1 (de) Adsorbermodul sowie Adsorberapparat zur Behandlung von Vollblut.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
DE3875016T2 (de) Therapeutikum zur behandlung von aids.
PT77020A (de) Mittel zur behandlung von wunden
ATE71307T1 (de) Verfahren zur behandlung von kontaktlinsen.
DE3785555T2 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
ATA84689A (de) Einrichtung zur behandlung von gasen
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.
DE3673017D1 (de) Vorrichtung zur behandlung von gliedmassen.
ATE91889T1 (de) Verfahren zur behandlung von brandwunden.
ATE91886T1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE3771706D1 (de) Behandlung von knochenschwund.
ATE75946T1 (de) Behandlung von unfruchtbarkeit.
ATE85522T1 (de) Mittel zur behandlung von chronisch entzuendlichen darmerkrankungen.
ATE74004T1 (de) Mischung zur behandlung von hypercholesterolemie.
ATE65394T1 (de) Behandlung von knochenschwund.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee